NorthStar Medical Secures Up to $185M Facility for Actinium-225 Expansion
NorthStar Medical secured an up-to-$185 million Hercules Capital growth facility, with $100 million funded upfront, to expand actinium-225 production and radiopharmaceutical manufacturing.
NorthStar Medical Technologies has secured a multi-year growth-capital facility of up to $185 million from Hercules Capital, including $100 million funded upfront, to expand medical-isotope production and radiopharmaceutical manufacturing in Beloit, Wisconsin.
The financing is debt-oriented growth capital—not a $185 million venture-equity round. The remaining $85 million represents additional facility capacity rather than cash already drawn. NorthStar and Hercules did not disclose the interest rate, maturity, collateral package, draw conditions or any equity-linked economics.
Financing snapshot
| Item | Detail |
|---|---|
| Financing type | Multi-year growth-capital facility |
| Total capacity | Up to $185 million |
| Funded upfront | $100 million |
| Additional capacity | Up to $85 million |
| Capital provider | Hercules Capital |
| Equity valuation | Not disclosed |
| Announced | September 29, 2026 |
| Use of proceeds | Isotope-production expansion and clinical and commercial radiopharmaceutical manufacturing |
That distinction matters for funding databases. Counting the entire $185 million as fresh equity would overstate both NorthStar's dilution and the amount already available on its balance sheet. The defensible treatment is a debt facility with $100 million funded and another $85 million of potential capacity.
Why isotope capacity is attracting growth capital
NorthStar supplies infrastructure for the expanding radiopharmaceutical market. These therapies attach a radioactive isotope to a targeting molecule designed to deliver radiation more precisely to cancer cells. Drug developers can create promising compounds, but clinical trials and commercialization still depend on reliable isotope supply and tightly controlled manufacturing.
Actinium-225 is especially important because its alpha emissions can deliver high-energy radiation over a short distance. It is also scarce. Production historically depended on limited government inventories and complex nuclear processes, creating a bottleneck for companies trying to run trials at scale.
NorthStar says it routinely produces no-carrier-added actinium-225 using electron-accelerator technology. It also works with copper-67 and is building a broader radiopharmaceutical contract-development and manufacturing operation. All claims about production scale, purity and technical performance remain company-reported unless independently validated.
An infrastructure rather than drug-development bet
The financing gives NorthStar exposure to the growth of radiopharmaceutical oncology without requiring the company to bet its future on one clinical asset. Its business can serve multiple pharmaceutical and biotechnology customers across isotope supply, development work and manufacturing.
That model may diversify program risk, but it introduces a different set of constraints:
- Capital intensity. Accelerator systems, cleanrooms and regulated manufacturing capacity require large investments before utilization is proven.
- Customer concentration. Early radiopharmaceutical markets may depend on a relatively small number of major drug developers.
- Regulatory execution. Medical-isotope and drug-product manufacturing must meet demanding quality, transport and release requirements.
- Technology competition. NorthStar's electron-accelerator route competes with reactor-, cyclotron- and other accelerator-based production approaches.
- Demand timing. Manufacturing capacity can be built faster than clinical programs reach approval, leaving assets underused.
The up-to structure helps manage some of that timing risk. Hercules can fund the first expansion phase while later availability may depend on contractual milestones or other conditions that have not been disclosed publicly.
The competitive field
NorthStar competes with medical-isotope suppliers including TerraPower Isotopes, Niowave, Ionetix and Eckert & Ziegler. The competitive question is not simply which company can produce actinium-225. Customers need consistent radionuclidic purity, reliable delivery, regulatory documentation and enough capacity to support programs from early trials through commercial launch.
NorthStar's stated advantage is co-location: commercial-scale isotope production and radiopharmaceutical CDMO services operate on the same campus. In principle, that can reduce transfers, shorten workflows and improve supply-chain control. Whether it creates a durable advantage will depend on customer validation, uptime, batch consistency and the economics of competing production routes.
Why Hercules Capital fits the transaction
Hercules Capital is a publicly traded specialty-finance company focused on senior secured venture and growth loans. The firm says its platform has committed more than $28 billion to over 700 companies since 2003 and manages more than $6 billion.
NorthStar's facility fits that model: a mature, asset-heavy life-sciences business needs substantial expansion capital but may prefer debt to a large dilutive equity financing. The trade-off is fixed financing obligations and lender protections that become more important if utilization or customer demand develops more slowly than planned.
What to watch
The next useful disclosures are operational rather than promotional:
- how much of the remaining $85 million becomes available and when;
- contracted customer demand supporting the new capacity;
- production volumes and batch reliability for actinium-225;
- progress from clinical manufacturing into commercial supply;
- any disclosed covenants, warrants or conversion rights attached to the facility.
NorthStar has secured enough upfront capital to accelerate construction and production. The investment case now turns on whether isotope scarcity becomes durable pricing power—or whether industry capacity expands faster than radiopharmaceutical programs reach the market.
Sources
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
